fostamatinib + digoxin

**fostamatinib + digoxin** is a combination of two small molecule drugs: fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, and digoxin, a cardiac glycoside. Fostamatinib is approved for chronic immune thrombocytopenia and acts as a prodrug for R406, which inhibits SYK. Digoxin is used for heart failure and certain arrhythmias by inhibiting the sodium-potassium ATPase. Co-administration results in drug-drug interaction due to fostamatinib's inhibition of P-glycoprotein (P-gp), increasing digoxin exposure. The combination is not marketed as a fixed product but is of clinical interest due to interaction potential, requiring monitoring of digoxin response and possible dose adjustment.